This medication is an essential blood-clotting factor, prescribed for controlling and preventing bleeding episodes in people with low levels of factor VIII (hemophilia A) and AHG deficiency. This product contains a man-made form of factor VIII, also called antihemophilic factor. This temporarily replaces the missing factor VIII, a protein (clotting factor) that is normally in the blood, so that the blood can clot and the bleeding can stop. Glycopegylated-antihemophilic factor was approved by the FDA in February 2019 which has an extended half-life.
IV- The recommended dose is 5 –10 U/kg, repeated 6 to 12 hourly.
It comes as a solution for injection to be administered by a healthcare provider into the vein. Warm diluent (Sterile Water for Injection, USP) and concentrate (Alphanate (antihemophilic factor) ) to at least room temperature (but not above 37 °C).
• Caution needed in pregnant and breastfeeding women.
• This medication should not be used to treat von Willebrand disease.
• It may cause dizziness, do not drive a car or operate machinery while taking this medication.
• Central Nervous System : Dizziness and headache.
• Skin : Itching, flushing of face, hives, swelling of face, lips, tongue, or throat, burning/redness/irritation at the injection site and unusual bruising or bleeding.
• Gastrointestinal : Stomach upset, stomach pain, loss of appetite, nausea, vomiting and sore throat.
• Miscellaneous : Fever, chills, difficulty in breathing, fast heart beat and chest tightness.
Avoid excess dosage. Should not be administered at a rate exceeding 10 mL/minute. Rapid administration of a Factor VIII concentrate may result in vasomotor reactions.
Store it in refrigerator (2 to 8°C), do not freeze it. May be stored at room temperature not to exceed 30 °C for up to 2 months.
Subscribe to our Free Newsletters!